Ginkgo Bioworks Holdings (DNA) Receivables - Net (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Receivables - Net for 7 consecutive years, with $13.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net fell 41.26% year-over-year to $13.0 million; the trailing twelve-month figure through Jun 2026 stood at $13.0 million (down 41.26% YoY), and the FY2025 full-year result was $24.0 million, up 9.92% from the prior year.
• Receivables - Net declined to $13.0 million in Q2 2026 per DNA's latest filing, from $19.8 million in the prior quarter.
• Across five years, Receivables - Net topped out at $171.6 million in Q2 2022 and bottomed at $13.0 million in Q2 2026.
• Historically, Receivables - Net has averaged $54.4 million across 5 years, with a median of $24.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net surged 154.42% in 2022, then plunged 78.79% in 2023.
• Over 5 years, Receivables - Net stood at $80.9 million in 2022, then slumped by 78.79% to $17.2 million in 2023, then climbed by 27.39% to $21.9 million in 2024, then grew by 9.92% to $24.0 million in 2025, then plunged by 45.84% to $13.0 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $13.0 million, $19.8 million, and $24.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.